{"nctId":"NCT01964352","briefTitle":"Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)","startDateStruct":{"date":"2013-11"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":813,"armGroups":[{"label":"tiotropium + olodaterol low dose","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium","Drug: olodaterol"]},{"label":"tiotropium + olodaterol high dose","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium","Drug: olodaterol"]},{"label":"tiotropium","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tiotropium"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"tiotropium","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"olodaterol","otherNames":[]},{"name":"tiotropium","otherNames":[]},{"name":"tiotropium","otherNames":[]},{"name":"olodaterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Diagnosis chronic obstructive pulmonary disease\n* Relatively stable airway obstruction with post FEV1 \\>=30 and \\< 80% predicted normal and post FEV1/ FVC \\< 70%\n* Male or female patients, 40 years of age or more\n* Smoking history more than 10 pack years\n\nExclusion criteria:\n\n* Significant diseases other than COPD\n* History of asthma\n* COPD exacerbation in previous 3 months\n* Completion of pulmonary rehabilitation program within previous 6 weeks or current participation in pulmonary rehabilitation program.\n* Pregnant or nursing women\n* Patients unable to comply with pulmonary medication restrictions","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"FEV1 AUC0-3h Response","description":"Forced expiratory volume in one second (FEV1) Area under the curve (AUC) 0-3h was calculated as the area under the FEV1-time curve from 0 to 3h post-dose using the trapezoidal rule, divided by the duration (3h) to report in litres. FEV1 AUC0-3h response was defined as FEV1 AUC0-3h minus baseline FEV1. The adjusted mean and standard error (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.014","spread":"0.014"},{"groupId":"OG001","value":"0.205","spread":"0.013"},{"groupId":"OG002","value":"0.285","spread":"0.013"},{"groupId":"OG003","value":"0.316","spread":"0.013"}]}]}]},{"type":"PRIMARY","title":"Trough FEV1 Response (Change From Baseline)","description":"Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours). It was calculated as the mean of the 2 FEV1 measurements performed 23 h and at 23 h 50 min after inhalation of study medication at day 85. Trough FEV1 response was defines as trough FEV1 minus baseline FEV1. The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.001","spread":"0.014"},{"groupId":"OG001","value":"0.135","spread":"0.014"},{"groupId":"OG002","value":"0.151","spread":"0.013"},{"groupId":"OG003","value":"0.163","spread":"0.013"}]}]}]},{"type":"PRIMARY","title":"St. George's Respiratory Questionnaire (SGRQ) Total Score","description":"This endpoint was evaluated based on the data from this individual trial and also based on the data from the combined dataset from this trial and the replicate study NCT02006732. The results for the combined dataset are included in the disclosure for NCT02006732 as specified in the analysis plan. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).\n\nThe adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.038","spread":"0.738"},{"groupId":"OG001","value":"39.637","spread":"0.717"},{"groupId":"OG002","value":"37.916","spread":"0.708"},{"groupId":"OG003","value":"37.144","spread":"0.710"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Vital Capacity (FVC) Response (Change From Baseline)","description":"Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours). It was calculated as the mean of the 2 FVC measurements performed 23 h and at 23 h 50 min after inhalation of study medication at day 85. Trough FVC response was defined as trough FVC minus baseline FVC. The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.025","spread":"0.023"},{"groupId":"OG001","value":"0.223","spread":"0.023"},{"groupId":"OG002","value":"0.233","spread":"0.022"},{"groupId":"OG003","value":"0.244","spread":"0.022"}]}]}]},{"type":"SECONDARY","title":"TDI Focal Score","description":"This endpoint was evaluated based on the data from this individual trial and also based on the data from the combined dataset from this trial and the replicate study NCT02006732. The results for the combined dataset are included in the disclosure for NCT02006732 as specified in the analysis plan. Mahler Transitional Dyspnoea Index (TDI) focal score was performed to measure the effect of the treatment on patients' dyspnoea.(Rating scale of 3 components - change in functional impairment, change in magnitude of tasks, change in magnitude of efforts. Worst score = -9, best score = +9).\n\nThe adjusted mean (SE) are obtained from fitting an MMRM model including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.113","spread":"0.196"},{"groupId":"OG001","value":"1.332","spread":"0.192"},{"groupId":"OG002","value":"1.839","spread":"0.189"},{"groupId":"OG003","value":"1.939","spread":"0.190"}]}]}]},{"type":"SECONDARY","title":"FVC AUC0-3h Response (Change From Baseline)","description":"The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect; spatial power covariance structure for within-patient errors and Kenward-Roger approximation of denominator degrees of freedom.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.011","spread":"0.025"},{"groupId":"OG001","value":"0.286","spread":"0.024"},{"groupId":"OG002","value":"0.387","spread":"0.023"},{"groupId":"OG003","value":"0.446","spread":"0.023"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":204},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis"]}}}